lithium has been researched along with Parkinsonian Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guttuso, T | 1 |
| Appukuttan, AT; Ayton, S; Berger, G; Bush, AI; Cherny, R; Duce, JA; Finkelstein, DI; Greenough, M; Lei, P; McGorry, P; Moon, S; Pantelis, C; Volitakis, I; Wood, SJ; Yung, A | 1 |
| Castro, AA; Ghisoni, K; Latini, A; Prediger, RD; Quevedo, J; Tasca, CI | 1 |
| McGrogan, M; Milliken, M; Poulos, S; Sanberg, PR; Saporta, S; Snable, G; Willing, AE; Zigova, T | 1 |
| Dallocchio, C; Mazzarello, P | 1 |
1 review(s) available for lithium and Parkinsonian Disorders
| Article | Year |
|---|---|
High lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced β-catenin-mediated activity.
Topics: alpha-Synuclein; Alzheimer Disease; Autophagy; beta Catenin; beta-Glucosidase; Brain Chemistry; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3 beta; Humans; Incidence; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lithium; Lithium Carbonate; Melanoma; Models, Biological; Mutation; Neuroprotective Agents; Nicotiana; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Parkinsonian Disorders; Smokers; Water; Wnt Signaling Pathway | 2019 |
4 other study(ies) available for lithium and Parkinsonian Disorders
| Article | Year |
|---|---|
Lithium suppression of tau induces brain iron accumulation and neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Humans; Iron; Lithium; Male; Mice; Mice, Knockout; Neurons; Parkinsonian Disorders; tau Proteins | 2017 |
Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Age Factors; Animals; Animals, Newborn; Avoidance Learning; Chromatography, High Pressure Liquid; Discrimination, Psychological; Disease Models, Animal; Dopamine; Drug Administration Schedule; Drug Interactions; Exploratory Behavior; Lithium; Male; Memory Disorders; Memory, Short-Term; Neuroprotective Agents; Neurotoxins; Olfaction Disorders; Parkinsonian Disorders; Rats; Rats, Wistar; Recognition, Psychology; Serotonin; Statistics, Nonparametric; Swimming; Valproic Acid | 2012 |
Lithium exposure enhances survival of NT2N cells (hNT neurons) in the hemiparkinsonian rat.
Topics: Animals; Brain Tissue Transplantation; Cell Line, Transformed; Cell Survival; Dopamine; Graft Survival; Growth Cones; Immunohistochemistry; Lithium; Male; Neostriatum; Neurons; Parkinsonian Disorders; Phosphopyruvate Hydratase; Rats; Rats, Sprague-Dawley; Stem Cells; Tyrosine 3-Monooxygenase | 2002 |
A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Humans; Lithium; Parkinsonian Disorders; Pramipexole; Severity of Illness Index; Thiazoles | 2002 |